1. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib 
Mark J. Koury, MD, John H. Newman, MD, John J. Murray, MD 
The American Journal of Medicine 
Volume 115, Issue 7, Pages (November 2003)
DOI: /S (03)

2. Figure
Effects of mepolizumab or imatinib on (A) blood eosinophil count and (B) serum interleukin 5 (IL-5) level in hypereosinophilic syndrome. On days 0, 14, and 43 (indicated by M), 750 mg of mepolizumab was given intravenously. On day 111 (indicated by I), oral imatinib mesylate was started at 400 mg/d. The normal range of eosinophils is shown in the hatched area. The normal range of IL-5 is less than 7 pg/mL.
The American Journal of Medicine  , DOI: ( /S (03) )